Background Over the past decade, there has been increasing availability of novel
therapeutics with improved tolerability and efficacy for advanced non-small cell lung cancer …

Objective Treatment options for non‐small‐cell lung cancer (NSCLC) have been evolving.
The goal of our study was to evaluate whether novel therapeutics are used in the elderly …

Background: Non-small cell lung cancer (NSCLC) commonly presents at advanced stage.
We previously reported systemic treatment uptake in stage IV NSCLC climbing from …

Introduction/background Systemic treatment for advanced non-small cell lung cancer
(NSCLC) is shifting from platinum-based chemotherapy to immunotherapy and targeted …

Background There are limited data on the role for chemotherapy in patients> 80 years old
with advanced stage non-small cell lung carcinoma (NSCLC). We used the National Cancer …

Abstract Introduction In France, 40% of patients diagnosed with lung cancer are≥ 70 years
old, but these are under-represented in clinical trials. Using data from the French …

Introduction There is a great need for data based on clinical trials for the older population in
order to improve treatment. Historically, the inclusion rate of older adults in clinical trials has …

Recent studies have revealed that few elderly patients receive chemotherapy for advanced
non-small cell lung cancer (NSCLC), even though it has been shown that the majority of …

Purpose Treatments for advanced non-small cell lung cancer (NSCLC) have evolved to
include targeted and immuno-oncology therapies, which have demonstrated clinical benefits …

Background Historically, older patients with advanced lung cancer have often received no
systemic treatment. Immunotherapy has improved outcomes in clinical trials, but its …